

## PRESSURE BIOSCIENCES INC.

14 Norfolk Avenue  
South Easton, MA 02375  
(T) 508-230-1828  
(F) 508-230-1829  
[info@pressurebiosciences.com](mailto:info@pressurebiosciences.com)

Mr. Richard T. Schumacher, CEO, President  
Dr. Edmund Y. Ting, SVP of Engineering  
Dr. Alexander V. Lazarev, Chief Science Officer  
Mr. John B. Hollister, Director, Marketing & Sales  
Mr. Daniel J. Shea, CPA, Senior Advisor - Finance

---

## STOCK OVERVIEW

Symbol:	PBIO	Recent Close:	\$2.01 (as of 5/20/21)
Exchange:	OTCQB	52-Week Range:	\$1.29 - \$3.06
Shares OS <sup>1</sup> :	5.2M (24M FD)	Market Capitalization <sup>2</sup> :	\$10.5M (\$48M FD)
Float:	~3.3M	Fiscal Year End:	December 31
Revenue (FY 2019)	\$1.8M	Transfer Agent:	Computershare

---

## COMPANY OVERVIEW

**Pressure BioSciences, Inc. (OTCQB: PBIO)** is a leader in the development & sale of innovative, enabling, high pressure platform technology solutions for the life sciences and other industries worldwide. Our products/services are based on three patented, high pressure platforms: (i) Pressure Cycling Technology ("PCT"), (ii) BaroFold Technology ("BaroFold"), and (iii) Ultra Shear Technology ("UST").

**The PCT Platform** uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., critical steps performed by hundreds of thousands of scientists worldwide, such as cell lysis and biomolecule extraction from tissue samples). Our primary focus is on making our recently released, GMP-compliant, next generation PCT-based Barocycler EXTREME instrument available globally to biopharmaceutical drug manufacturers for use in the design, development, characterization, and quality control of biotherapeutic drugs. The PCT Platform is also used in such areas as biomarker and target discovery, soil & plant biology, anti-bioterror, and forensics. We currently have over 300 PCT instrument systems placed in approximately 200 academic, government, pharmaceutical, and biotech research laboratories worldwide. There are over 120 independent publications highlighting the advantages of using the PCT Platform in scientific research studies, many from worldwide key opinion leaders.

**The BaroFold Platform** can be used to significantly improve the quality and production costs of protein biotherapeutics. It employs high pressure for the disaggregation and controlled refolding of proteins to their desired native structures at yields and efficiencies not achievable using existing technologies. The BaroFold Platform has been shown to remove protein aggregates in biotherapeutic drug manufacturing, thereby improving product efficacy, safety, and cost for both new-drug entities and biosimilar (follow-on biologic) products. The BaroFold Platform can help companies to more efficiently and cost effectively create, accelerate development, and manufacture novel protein biotherapeutics and follow-on biologics, and perform critical rescue/rework on aggregated or misfolded products. It is scalable and practical for standard manufacturing processes. This unique technology platform can help protein-based biopharmaceutical companies create and manufacture high quality, novel protein biotherapeutics and lower the cost of existing formulations. Research and manufacturing licenses are available.

**The UST Platform** is based on the use of intense shear forces from ultra-high pressure (greater than 20,000 psi) valve discharge with precisely controlled temperatures. UST has been shown to turn hydrophobic (water-repelling) oil-based nutrients, therapeutics, or other active ingredients into stable, effectively water-soluble nanoemulsion formulations. Such formulations are expected to gain enormous success in many markets, including pharmaceuticals, nutraceuticals, (e.g., water soluble, medically important plant extracts, such as CBD-enriched plant oil), cosmeceuticals, as well as broad food & beverage, agriculture, and industrial opportunities (e.g., inks, paints, lubricants, etc.). We believe that UST has the potential to play a significant role in many commercially important areas, including (i) stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water), delivering superior-performing products in diverse applications, and (ii) the preparation of higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies, e.g., dairy products. The UST Platform is currently being licensed into initial applications and developed for commercialization.

---

## INVESTMENT HIGHLIGHTS

- PBI has Proven Core Technology with Multiple Applications (Over 300 Pressure Systems Installed Globally)
  - PBI has Three Novel, Enabling, Patented & Proprietary Pressure-based Platforms: PCT, BaroFold, & UST
  - PCT Platform Breaks Through Bottlenecks to Enable/Accelerate Discovery & QC in Drug Development
  - BaroFold Platform Improves and Reduces production Costs of Protein Drug Therapeutics through Disaggregation and Controlled Refolding
  - UST Platform Makes Safer, More Bioavailable, Highly Stable Nanoemulsions for Multiple Major Markets
  - Significant Worldwide Market Opportunities: PCT and BaroFold (BioPharma R&D and QC \$526B); UST (CBD \$44B; Cosmeceuticals \$805B; BioPharma Manufacturing \$900B; Food and Beverages \$5.65T)
- 

## RECENT & KEY ANNOUNCEMENTS

- May 19, 2021: PBI Reports Resurgent Growth in 1<sup>st</sup> Quarter 2021: Total Revenue Up 121%, Instrument Sales Up 235%, Consumable Sales Up 81%, Gross Margins Up (31-60%), and Operating Loss Down 23%.
  - May 13: Pressure BioSciences Awarded Three Additional Patents for Revolutionary Ultra Shear Technology (“UST”) Platform: Japan, Australia, and China.
  - April 14: Pressure BioSciences Finalizes Plan to Acquire Global Eco-Friendly Agrochemical Supplier. Company Expects Acquisition to be Accretive with Sustained Profitable Revenue Growth.
  - March 15: Pressure BioSciences discusses partnerships with Leica Microsystems (cancer diagnostics) and Ohio State University (food industry consortium) with the Stock Day Podcast.
  - March 4: Transformative impact of food industry consortium formed by Pressure BioSciences and Ohio State University discussed in showcase video from Emerging Technology Insider.
  - February 24: PBI and Ohio State University announce formation of a food industry consortium to advance commercialization of the Company’s Ultra Shear Technology (UST) platform.
  - February 8: Company announces plans to acquire the assets of a global eco-friendly agrochemical supplier.
  - January 20, 2021: PBI targets revolution in effectiveness of therapeutics via improved drug delivery and dosing safety; announces collaboration with SinuSys Corp to improve and optimize their lead sinus health product candidate prior to Phase IIb trials.
  - December 17, 2020: Company reports its PCT Platform is at the forefront in generating pivotal findings by diverse COVID-19 research teams in the USA, China, and Europe.
  - December 15: Company announces planned presentation on December 17, 2020 at the Life Sciences Investor Forum: <https://www.lifesciencesinvestorforum.com/>
  - December 4: Company Announces that its proposed acquisition partner Cannaworx, Inc. has set a December 2020 launch date for its FDA Registered Immune Booster product.
  - November 17: Company Reports Third Quarter 2020 Financial Results – instrument sales increase 68%, total revenue increases 7%, operating loss decreases 23%.
  - November 11: Company awarded first U.S. patent for revolutionary Ultra Shear Technology™ (UST™) platform.
  - October 6: Company achieves critical milestone in revolutionary nanoemulsification technology development; enters production era for commercial system (BaroShear K45) development.
  - August 12: PBI awarded pivotal U.S. patent for novel, high pressure enhanced consumable device. New patent secures and protects PBI’s best-selling PCT sample preparation consumable product, the PCT MicroPestle.
  - June 20: PBI and Leica Microsystems sign worldwide co-marketing alliance: combination of proprietary technologies expected to accelerate cancer R&D with innovative tumor processing workflow.
  - June 4: PBI announces first manufacturing build completely sold out for revolutionary UST System for processing hemp-derived cannabinoid oil into stable, water-soluble nanoemulsions.
  - April 16: PBI and RedShiftBio demonstrate potential of combining proprietary technologies to enable new tool for development and production of biotherapeutics.
  - February 27: PBI launches new era in preparation of water-soluble nanoemulsions for CBD and other valuable oils with opening of UST Demonstration Laboratory.
  - January 30: PBI announced acceleration of UST Platform rollout for water-soluble CBD with planned release of additional BaroShear product – a benchtop, R&D scale, BaroShear “Mini” instrument.
  - January 24: PBI announced significant new order and near sellout on revolutionary nanoemulsification system for water-soluble CBD oil. Company said that additional orders are expected shortly.
  - January 9, 2020: PBI reported that the number of published scientific papers in 2019 citing the advantages of the Company’s PCT Platform remained strong, with over 20 journal articles for the second straight year.
- 

## BOARD OF DIRECTORS

- Mr. Jeffrey N. Peterson, Chairman
- Mr. Kevin A. Pollack, Esq.
- Mr. Vito Mangiardi
- Dr. Mickey Urdea
- Mr. Richard T. Schumacher

1. Shares Outstanding (as of May 13, 2020) – includes approximately 5.2M Common Shares (CS), 1.3M CS Equivalents (CSE) from outstanding stock options, 8.5M CSE from Preferred Stock Series D, G, H, J, K, AA, and 9.0M CSE from convertible loans on an as-converted basis.
2. Fully Diluted Market Capitalization is calculated using Common Stock OS and Common Equivalent Shares OS on a Fully Diluted basis.